Xoma Corp. (XOMA) Given Average Rating of “Hold” by Brokerages
Xoma Corp. (NASDAQ:XOMA) has been assigned a consensus rating of “Hold” from the six analysts that are presently covering the stock. Five analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $2.50.
XOMA has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of Xoma Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 26th. Cowen and Company reaffirmed a “market perform” rating on shares of Xoma Corp. in a research note on Monday, September 19th. Wedbush reaffirmed an “outperform” rating and set a $3.00 price objective (up previously from $1.42) on shares of Xoma Corp. in a research note on Friday, September 16th. Finally, Jefferies Group reaffirmed a “hold” rating on shares of Xoma Corp. in a research note on Friday, August 5th.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bellevue Group AG bought a new position in Xoma Corp. during the first quarter worth approximately $174,000. Geode Capital Management LLC boosted its stake in shares of Xoma Corp. by 1.3% in the first quarter. Geode Capital Management LLC now owns 600,488 shares of the company’s stock worth $464,000 after buying an additional 7,576 shares during the last quarter. Wedbush Securities Inc. boosted its stake in shares of Xoma Corp. by 4.1% in the second quarter. Wedbush Securities Inc. now owns 404,396 shares of the company’s stock worth $223,000 after buying an additional 15,827 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of Xoma Corp. during the second quarter worth about $185,000. Finally, Spark Investment Management LLC boosted its stake in shares of Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock worth $112,000 after buying an additional 102,400 shares during the last quarter. 17.13% of the stock is owned by institutional investors.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/xoma-corp-xoma-given-average-rating-of-hold-by-brokerages.html
Shares of Xoma Corp. (NASDAQ:XOMA) traded down 3.3636% during mid-day trading on Tuesday, reaching $0.4252. 363,196 shares of the company traded hands. Xoma Corp. has a 52-week low of $0.42 and a 52-week high of $2.03. The company has a market capitalization of $51.27 million, a P/E ratio of 38.6545 and a beta of 2.87. The firm’s 50 day moving average price is $0.55 and its 200-day moving average price is $0.64.
Xoma Corp. (NASDAQ:XOMA) last announced its earnings results on Wednesday, August 3rd. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.01. The company had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.84 million. During the same period last year, the firm earned ($0.20) earnings per share. Equities analysts predict that Xoma Corp. will post ($0.47) earnings per share for the current fiscal year.
About Xoma Corp.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.